Amarin Corporation Reports Q2 2026 Financial Results: Early Success in International Strategy, Lower Operating Expenses, and Positive Cash Flow

Key Highlights for Investors

• Global In-Market Demand Grows 59%: Early signs of success in Amarin’s fully partnered international commercial strategy, particularly in Europe and Asia, with total in-market demand for VASCEPA/VAZKEPA rising 59% year-over-year across the partner network.
• Significant Cost Reductions and Positive Cash Flow: Operating expenses declined by 59% (\$39.3 million) compared to Q2 2025. Excluding restructuring charges, expenses dropped 38% (\$16.6 million), achieving the previously announced \$70 million annual savings initiative. The company generated positive cash flow for the third consecutive quarter and remains debt-free.
• U.S. Market Share Maintained and Grows: U.S. share of the IPE (icosapent ethyl) market increased to 48% in Q2 2026 from 43% in Q2 2025, with branded VASCEPA prescriptions up 14% year-over-year.
• Transformation via Recordati Partnership: A June 2025 exclusive long-term license and supply agreement with Recordati S.p.A. for 59 countries in Europe enabled a shift to a partnered model, significantly reducing operating expenses while expanding market reach.
• Financial Strength: Cash increased to \$314.6 million as of June 30, 2026 (from \$302.6 million at December 31, 2025). Amarin expects cash to grow by approximately 10% by the end of FY2026.
• Ongoing Strategic Review: Amarin continues to work with Barclays, its exclusive financial advisor, to explore further value-enhancing opportunities for shareholders.

Detailed Financial and Operational Performance

International Expansion and Volume Growth

• Amarin’s strategic shift to a partnered international model with Recordati has rapidly accelerated in-market demand:
  • 59% overall global in-market demand growth in Q2 2026 vs. Q2 2025
  • Europe: 69% growth in in-market demand for VAZKEPA
  • China: 90% year-to-date volume growth compared to previous year
  • VASCEPA/VAZKEPA now commercially available in 22 countries worldwide, including 11 in Europe, with further launches imminent in Singapore and South Korea

Financial Results at a Glance

Revenue Drivers and Headwinds

• Net Revenue Decline: The revenue drop is mainly due to a \$25M upfront payment from the Recordati agreement in Q2 2025 (non-recurring), ongoing generic competition in the U.S., and a transition to a partnered model in Europe. However, demand for branded VASCEPA in the U.S. increased.
• Licensing & Royalties: Dropped 88% year-over-year due to the absence of the Recordati one-off payment. Ongoing royalties from Recordati are now recognized.
• Operating Expenses: SG&A costs fell 43%, reflecting the completed Global Restructuring Plan and transition to the Recordati model. R&D spend was stable. COGS increased 22% due to higher product volumes.
• Inventory Management: Inventories declined by \$19.5M from March 31, 2026, and by \$31.8M since December 31, 2025, reflecting improved working capital management.

Shareholder-Relevant and Price-Sensitive Developments

• Early Signs of Turnaround: The company is now generating positive cash flow and has completed a major cost-cutting program, providing a more sustainable financial base for future growth.
• International Potential: The Recordati partnership and strong international in-market demand growth are key drivers for future revenues, with ongoing launches and regulatory activities in Europe and Asia. This could materially add to future revenues and margins as the partner model scales.
• U.S. Market Leadership: Despite generic competition, Amarin has grown U.S. market share and increased branded prescription volume, indicating brand resilience and effective commercial execution.
• Ongoing Strategic Review: The company is actively working with Barclays on potential value-enhancing transactions or strategic alternatives, a process that could result in significant corporate actions affecting share value.

Outlook for Full Year 2026

• Continued global growth, especially in Recordati-licensed international markets
• Stabilized U.S. VASCEPA volumes
• Maintenance of lower operating expense profile
• Expectation for cash to grow by approximately 10% by year-end 2026

Product and Market Information

• VASCEPA/VAZKEPA (icosapent ethyl) is a leading cardiovascular drug with approvals across the U.S., Canada, Europe, China, Australia, and Middle East, backed by robust clinical evidence.
• Market opportunity in Europe is substantial, with cardiovascular disease affecting 62 million people and an economic burden of €282 billion annually.
• Amarin’s global distribution now covers nearly 100 markets via direct and partnered sales models.

Risks and Considerations

• Generic competition continues to pressure U.S. pricing, although branded demand is resilient.
• Quarterly revenue volatility is possible as the transition to a partnered model in Europe proceeds and shipments vary by partner market.
• Forward-looking statements are subject to risks related to execution, regulatory, market access, and competitive dynamics.

Conference Call Information

Amarin will host a conference call on July 29, 2026, at 8:00 a.m. ET. Details and a replay are available on the investor relations section of Amarin’s website.

Conclusion

Amarin’s Q2 2026 results reveal a company in transition but gaining momentum: positive international demand trends, a leaner cost structure, and a robust cash position. The ongoing strategic review and further execution of the international model could be highly price-sensitive catalysts for investors.

Disclaimer: This article is for informational purposes only and does not constitute investment advice. Investors should review Amarin’s full filings, consider their own circumstances, and consult with a financial advisor before making investment decisions. Forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially.

View AMARIN CORP PLC\UK Historical chart here